Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease, with a global prevalence of approximately 24% in the general population. It is caused by fat accumulation in the liver secondary to insulin resistance, visceral obesity, and/or features of metabolic syndrome. A genetic susceptibility contributes to the phenotype, accounting for a more severe course of liver disease and the observed clinical variability. In fact, despite liver steatosis being considered a relatively benign entity, inflammation related to oxidative stress and lipid-derived damage may lead to non-alcoholic steatohepatitis (NASH), which constitutes the progressive disease. Accumulation of hepatic fibrosis can lead to cirrhosis and provide the environment for hepatocellular carcinoma. Obese and diabetic individuals represent a well-acknowledged high risk population. The assessment of liver fibrosis plays a crucial role in clinical setting, as liver-related mortality increases parallel to fibrosis stage. A liver biopsy is currently considered the reference standard for the diagnosis of NASH and the fibrosis stage, but many non-invasive tools are used with the aim of replacing histology for diagnosis and prognosis purposes. Blood based scores and liver stiffness are the most widely used and validated tools to assess liver fibrosis. Management of NAFLD resides on environmental interventions, including diet and physical activity to induce weight loss, and avoiding harmful nutrients, including fructose-sweetened beverages and high glycemic index foods, that are directly implied in liver injury. Multiple trials with investigational drugs are currently explored to treat fibrosing NASH, with promising results and it can be expected that a liver direct therapy aiming at steatohepatitis and fibrosis will become available soon.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alqahtani SA, Schattenberg JM (2021) Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn:1–14
Armandi A, Schattenberg JM (2021) Beyond the paradigm of weight loss in non-alcoholic fatty liver disease: from pathophysiology to novel dietary approaches. Nutrients 13(6):1977
Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690
Bazerbachi F, Vargas EJ, Rizk M et al (2021) Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19:146–154 e144
Bedossa P, Poitou C, Veyrie N et al (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751–1759
Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307
Cusi K, Orsak B, Bril F et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165:305–315
Dinani AM, Kowdley KV, Noureddin M (2021) Application of artificial intelligence for diagnosis and risk stratification in NAFLD and NASH: the state of the art. Hepatology 74(4):2233–2240
Docherty M, Regnier SA, Capkun G et al (2021) Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. J Am Med Inform Assoc 28:1235–1241
Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557–1565
EASL (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402
EASL (2021) EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2020 update. J Hepatol 75(3):659–689
Erhardtsen E, Rasmussen DGK, Frederiksen P et al (2021) Determining a healthy reference range and factors potentially influencing PRO-C3 – a biomarker of liver fibrosis. JHEP Rep 3:100317
Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202–209
Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69:896–904
Francque SM, Bedossa P, Abdelmalek MF et al (2020) A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. Contemp Clin Trials 98:106170
Garcia-Tsao G, Bosch J, Kayali Z et al (2020) Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol 72:885–895
Golabi P, Paik J, Fukui N et al (2019) Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes 37:65–72
Goldberg D, Ditah IC, Saeian K et al (2017) Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152:1090–1099 e1091
Harrison SA, Bashir MR, Guy CD et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394:2012–2024
Harrison SA, Goodman Z, Jabbar A et al (2020) A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol 72:816–827
Karsdal MA, Kraus VB, Shevell D et al (2021) Profiling and targeting connective tissue remodeling in autoimmunity – a novel paradigm for diagnosing and treating chronic diseases. Autoimmun Rev 20:102706
Kuchay MS, Krishan S, Mishra SK et al (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 41:1801–1808
Lassailly G, Caiazzo R, Ntandja-Wandji LC et al (2020) Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159:1290–1301 e1295
Lazarus JV, Anstee QM, Hagström H et al (2021) Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 18(10):717–729
Loomba R (2018) Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol 68:296–304
Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124
Noureddin M (2021) Artificial intelligence in NASH histology: human teaches a machine for the machine to help humans. Hepatology 74:9–11
Salomone F, Sharaiha RZ, Boskoski I (2020) Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives. Liver Int 40:1262–1268
Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675–1685
Sanyal AJ, Harrison SA, Ratziu V et al (2019) The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70:1913–1927
Schattenberg JM, Lazarus JV, Newsome PN et al (2021) Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int 41:1227–1242
Schuppan D, Ashfaq-Khan M, Yang AT et al (2018) Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol 68-69:435–451
Vali Y, Lee J, Boursier J et al (2020) Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 73:252–262
Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84
Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20
Younossi ZM, Golabi P, de Avila L et al (2019a) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71:793–801
Younossi ZM, Ratziu V, Loomba R et al (2019b) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394(10215):2184–2196
Zhang H, Gao C, Fang L et al (2013) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 48:78–87
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Armandi, A., Schattenberg, J.M. (2021). NAFLD and NASH: The Metabolically Diseased Liver. In: Eckel, J., Clément, K. (eds) From Obesity to Diabetes. Handbook of Experimental Pharmacology, vol 274. Springer, Cham. https://doi.org/10.1007/164_2021_561
Download citation
DOI: https://doi.org/10.1007/164_2021_561
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99994-0
Online ISBN: 978-3-030-99995-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)